Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,519 total articles
Quince Therapeutics reported that its Phase 3 NEAT study of dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) did not achieve its primary or key secondary endpoints, prompting management to stop development of the therapy. The stock plunged sharply, and analysts at Citizens altered their stance while flagging limited cas…
RBC Capital has reaffirmed an Underperform rating on Whirlpool Corporation (WHR) with a $51.00 price target, implying roughly a 34% decline from the stock's current $76.96 trading price. The call reflects concerns around a missed Q4 top line, guidance the firm deems difficult to achieve for fiscal 2026, below-consensus EBITDA revisions, weak margin…
BMO Capital has begun coverage of Elevra Lithium (NASDAQ:ELVR), giving the stock an Outperform rating and setting a price target of A$12.50. The firm highlighted Elevra's enhanced standing as a North American lithium producer following the Sayona-Piedmont merger, the removal of a restrictive offtake agreement, and an improved balance sheet. Separat…
Oppenheimer increased its 12-month price objective for Caterpillar to $729 from $700 while retaining an Outperform rating, citing sizable backlog expansion and record order intake in key segments. Caterpillar reported stronger-than-expected fourth-quarter 2025 results, including EPS of $5.16 and revenue of $19.1 billion, and the stock rose on the n…
Morgan Stanley reduced its rating on Fractyl Health Inc (GUTS) from Overweight to Equalweight and slashed the firm's price target to $2.00 from $8.00 after six-month randomized data for the Revita weight-maintenance treatment showed encouraging trends but missed expectations. The stock has fallen sharply and the firm flagged questions about Revita'…
Jones Trading has begun coverage of Rein Therapeutics (NASDAQ:RNTX) with a Buy rating and a price target of $8.00, implying substantial upside from the current share price of $1.43. The research note emphasizes the company’s commercial-stage dual-balloon catheter, RenovoCath, and recent clinical and regulatory milestones for lead drug candidate LTI…
Compass Point shifted its rating on Circle Internet Group (CRCL) from Sell to Neutral and cut its price target to $60 from $75, citing a strong correlation with cryptocurrency price moves and concentrated use of the USDC stablecoin in speculative channels. Multiple firms have adjusted views and targets on Circle amid rising USDC circulation and upc…
Texas Capital Securities has begun coverage of Figure Technology (NASDAQ: FIGR) with a Buy rating and a $82.00 price target, implying roughly 21% upside from current levels. The firm highlights Figure's leading position in tokenizing real-world assets and credits its HELOC origination and securitization business for most of the company's revenue. T…
Evercore ISI has reaffirmed its Outperform rating and $320 price target on Reddit (NYSE: RDDT) after a webinar with RECHO CEO Jonny Waite. The firm points to robust advertiser demand, high gross margins and strong revenue growth, while warning that an underdeveloped advertising infrastructure limits the platform's ability to scale ad spend.
Tigress Financial Partners has reiterated a Buy rating on Mobileye N.V. (MBLY) with a $25.00 price target, pointing to growing monetization of higher-value ADAS offerings and strategic expansion into Physical AI and humanoid robotics via the Mentee Robotics acquisition. The stock is trading near its 52-week low and is considered undervalued on Fair…
Oppenheimer lowered its price target on Docebo Inc. (DCBO) to $25 from $35 while retaining an Outperform rating. The revision follows Docebo’s announcement of a substantial issuer bid to repurchase up to $60 million of shares at $20.40 each and comes alongside initial fiscal 2026 guidance and the acquisition of 365Talents.
William Blair analyst Sharon Zackfia reiterated an Outperform rating on Royal Caribbean Cruises, citing record booking momentum into 2026 and better-than-expected earnings guidance. The cruise operator reported steady fourth-quarter 2025 results, introduced loyalty program enhancements, and saw new ships and resort offerings draw strong guest inter…
Stifel has increased its price target on Brinker International to $210 from $200 and maintained a Buy rating after the company reported fiscal second-quarter 2026 results that exceeded expectations. The firm nudged up its fiscal 2026 and 2027 EPS estimates and cited resilient Chili's same-store sales despite a headwind from Winter Storm Fern. Other…
Raymond James reduced its price target for Mastercard to $631 from $707 while preserving an Outperform rating after the company's fourth-quarter results. The firm's analysts see the EPS beat as driven by tax and grant benefits rather than top-line strength, but note supportive expense guidance and product initiatives that underpin a broadly constru…
Needham has increased its price target on Allegro MicroSystems to $41 from $37 and reaffirmed a Buy rating following quarterly results that outperformed expectations. The upgrade reflects stronger bookings, a healthier backlog, favorable pricing assumptions for calendar 2026 and growth across Automotive and Data Center end markets.
UBS has increased its gold price projection to $6,200 per ounce for March, June and September 2026, up from a prior $5,000 target. The bank cites robust central bank purchases, elevated ETF inflows and rising bar-and-coin demand, alongside lower U.S. real rates and heightened economic and political uncertainty. The SPDR Gold Shares ETF (GLD) has re…
Freedom Capital Markets raised Abbott Laboratories (ABT) from Hold to Buy while reducing its 12-month price target to $120 from $130. The move comes after Abbott reported a weaker-than-expected fourth quarter for 2025 and as the stock trades near its 52-week low. The research firm cited long-term upside tied to the planned integration of Exact Scie…
Freedom Capital Markets raised its price target on Tesla to $440 from $406 while holding a neutral stance on the stock. The firm pointed to fourth-quarter 2025 results that modestly exceeded consensus and flagged Robotaxi progress as a potential offset to ongoing EV demand weaknesses into 2026. Analysts remain divided on valuation and near-term out…
UBS raised its price objective on Tapestry Inc. to $125 from $123 while retaining a Neutral rating, citing strong fundamentals in the Coach brand and an anticipated modest Q2 earnings beat. Multiple analysts have increased forecasts and targets after robust fiscal-quarter results, though UBS and others warn that the market may already be pricing in…
Evercore ISI maintained an Outperform rating on IBM with a $345 price target but removed the stock from its Tactical Outperform list after the company posted stronger-than-expected fourth-quarter results. IBM beat revenue and EPS estimates, recorded broad-based segment growth, and issued 2026 guidance above Street expectations for sales and free ca…
UBS reiterated a Buy rating and a $600 price target on Microsoft after the company's latest earnings release, pointing to a favorable capacity outlook and potential backlog conversion. Microsoft reported double-digit revenue and EPS growth, while Azure and Microsoft 365 growth rates landed just below UBS estimates. Multiple other brokerages adjuste…
UBS has reaffirmed a Buy rating on AT&T and held its $31.00 price target after the carrier reported stronger-than-expected fourth-quarter results. The firm described the quarter as solid and said AT&T’s expansive fiber footprint and convergence advantages point to accelerating profit growth and rising free cash flow. Other analysts offered mixed re…
Benchmark Capital reiterated a Hold rating on Canadian Pacific Kansas City (NYSE: CP) after the company’s fourth-quarter 2025 results, which fell marginally short of expectations. Management provided initial 2026 guidance targeting operating ratio improvement and low-double digit core adjusted diluted EPS growth, supported by synergies and a foreca…
Benchmark has reaffirmed a Hold rating on Meta Platforms Inc. (META), pointing to uncertain returns on invested capital and a pronounced rise in capital and operating expenditures. While Meta benefits from healthy gross margins and recent revenue beats, the firm says high AI compensation and elevated capex leave the company’s medium-term profitabil…
UBS raised its price target on Meta Platforms to $872 from $830 and kept a Buy rating, citing guidance for 2026 operating and capital spending and the company’s expected realization of AI-driven revenue streams. The firm highlighted substantial ad monetization dollar growth and strong margin and revenue trends, while other brokerages also adjusted …
